RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer

Olav Engebraaten; Christina Yau; Kristian Berg; Elin Borgen; Øystein Garred; Maria E. B. Berstad; Ane S. V. Fremstedal; Angela DeMichele; Laura van ’t Veer; Laura Esserman; Anette Weyergang

doi:10.1038/s41467-021-26018-z

Nature Communications (Nov 2021)

RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer

Olav Engebraaten,
Christina Yau,
Kristian Berg,
Elin Borgen,
Øystein Garred,
Maria E. B. Berstad,
Ane S. V. Fremstedal,
Angela DeMichele,
Laura van ’t Veer,
Laura Esserman,
Anette Weyergang

Affiliations

Olav Engebraaten: Department of Oncology, Oslo University Hospital
Christina Yau: Departments of Surgery and Laboratory Medicine, University of California San Francisco
Kristian Berg: Institute for Cancer Research, Oslo University Hospital
Elin Borgen: Department of Pathology, Oslo University Hospital
Øystein Garred: Department of Pathology, Oslo University Hospital
Maria E. B. Berstad: Institute for Cancer Research, Oslo University Hospital
Ane S. V. Fremstedal: Institute for Cancer Research, Oslo University Hospital
Angela DeMichele: Department of Medicine, Perelman School of Medicine, University of Pennsylvania
Laura van ’t Veer: Departments of Surgery and Laboratory Medicine, University of California San Francisco
Laura Esserman: Departments of Surgery and Laboratory Medicine, University of California San Francisco
Anette Weyergang: Institute for Cancer Research, Oslo University Hospital

DOI: https://doi.org/10.1038/s41467-021-26018-z
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Antibody Drug Conjugates (ADCs) are emerging in the field of precision cancer medicine. Here, the authors suggest using endocytosis as a predictive biomarker for response

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal